Wegovy 1 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26F0M66
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,907
Award facts
- Contract value 100% obligated
- $24,906.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 29, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $24,906.86 to AmerisourceBergen Drug Corp for the supply of Wegovy 1 mg/0.5 mL pens in 0.5 mL dosages. This firm fixed-price delivery order is unclassified and carries an ultimate completion date of January 30, 2026, with performance to occur at the contractor's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery against AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., functions as a major pharmaceutical distributor and critical vendor for federal medical procurement needs across the Department of Defense healthcare enterprise. The company's DLA IDC encompasses a broad spectrum of pharmaceutical products and medical supplies including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for Wegovy, a GLP-1 receptor agonist medication used in diabetes and weight management treatment, reflects DLA's ongoing procurement of essential pharmaceutical commodities to support military treatment facilities and healthcare programs globally.
Quick answers
Who was awarded contract SPE2DR26F0M66?
SPE2DR26F0M66 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26F0M66 worth?
The government has obligated $24,907 on SPE2DR26F0M66.
Is contract SPE2DR26F0M66 an order under another contract?
Yes. SPE2DR26F0M66 is a delivery order under SPE2DR25D2207, an indefinite delivery contract.
Was contract SPE2DR26F0M66 competed?
The extent of competition for SPE2DR26F0M66 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award